AIM ImmunoTech Inc. (NYSE:AIM) CEO Purchases $10,819.80 in Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels bought 60,110 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were purchased at an average cost of $0.18 per share, with a total value of $10,819.80. Following the acquisition, the chief executive officer now directly owns 1,552,968 shares of the company’s stock, valued at approximately $279,534.24. This represents a 4.03 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AIM ImmunoTech Price Performance

AIM opened at $0.21 on Friday. The business’s fifty day moving average is $0.26 and its 200-day moving average is $0.33. AIM ImmunoTech Inc. has a 52-week low of $0.16 and a 52-week high of $0.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75.

Hedge Funds Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC acquired a new stake in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. Hedge funds and other institutional investors own 12.02% of the company’s stock.

Analyst Upgrades and Downgrades

AIM has been the subject of several analyst reports. Maxim Group dropped their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, October 22nd. Ascendiant Capital Markets dropped their price target on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).